Found: 182
Select item for more details and to access through your institution.
Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia.
- Published in:
- Clinical & Molecular Hepatology, 2024, v. 30, n. 3, p. 577, doi. 10.3350/cmh.2024.0157
- By:
- Publication type:
- Article
Profiles associated with significant hepatic fibrosis consisting of alanine aminotransferase >30 U/L, exercise habits, and metabolic dysfunction‐associated steatotic liver disease.
- Published in:
- Hepatology Research, 2024, v. 54, n. 7, p. 655, doi. 10.1111/hepr.14020
- By:
- Publication type:
- Article
Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation.
- Published in:
- Journal of Gastroenterology, 2024, v. 59, n. 7, p. 598, doi. 10.1007/s00535-024-02100-3
- By:
- Publication type:
- Article
Hepatic inflammation and fibrosis are profiles related to mid‐term mortality in biopsy‐proven MASLD: A multicenter study in Japan.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 59, n. 12, p. 1559, doi. 10.1111/apt.17995
- By:
- Publication type:
- Article
A Significant Increase in the Serum Carbohydrate Antigen 19-9 Level Accompanied by Acute Cholecystitis and Choledocholithiasis: A Case Report and Review of the Literature.
- Published in:
- Internal Medicine, 2024, v. 63, n. 12, p. 1713, doi. 10.2169/internalmedicine.2597-23
- By:
- Publication type:
- Article
Impact of metabolic dysfunction‐associated fatty liver disease on the incidence of Helicobacter pylori‐negative gastric cancer.
- Published in:
- Hepatology Research, 2024, v. 54, n. 6, p. 540, doi. 10.1111/hepr.14010
- By:
- Publication type:
- Article
Immunoglobulin-like transcript 2 as an impaired anti-tumor cytotoxicity marker of natural killer cells in patients with hepatocellular carcinoma.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1389411
- By:
- Publication type:
- Article
Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study.
- Published in:
- Clinical & Molecular Hepatology, 2024, v. 30, n. 2, p. 225, doi. 10.3350/cmh.2023.0515
- By:
- Publication type:
- Article
Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD.
- Published in:
- Clinical & Molecular Hepatology, 2024, v. 30, n. 2, p. 263, doi. 10.3350/cmh.2023.0557
- By:
- Publication type:
- Article
Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease.
- Published in:
- Clinical & Molecular Hepatology, 2024, v. 30, n. 2, p. 266, doi. 10.3350/cmh.2024.0028
- By:
- Publication type:
- Article
Meta‐analysis: Prevalence and impact of alcohol abstinence in alcohol‐associated cirrhosis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 59, n. 6, p. 730, doi. 10.1111/apt.17888
- By:
- Publication type:
- Article
Resistance exercise in combination with aerobic exercise reduces the incidence of serious events in patients with liver cirrhosis: a meta-analysis of randomized controlled trials.
- Published in:
- Journal of Gastroenterology, 2024, v. 59, n. 3, p. 216, doi. 10.1007/s00535-023-02060-0
- By:
- Publication type:
- Article
Impact of non‐obese metabolic dysfunction‐associated fatty liver disease on risk factors for the recurrence of esophageal squamous cell carcinoma treated with endoscopic submucosal dissection: A multicenter study.
- Published in:
- Hepatology Research, 2024, v. 54, n. 2, p. 201, doi. 10.1111/hepr.13973
- By:
- Publication type:
- Article
Case report: A case of fulminant type 1 diabetes mellitus after COVID-19 vaccination during treatment of advanced gastric cancer: pitfall in managing immune-related adverse events.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2023.1264281
- By:
- Publication type:
- Article
Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD.
- Published in:
- Clinical & Molecular Hepatology, 2024, v. 30, n. 1, p. 121, doi. 10.3350/cmh.2023.0437
- By:
- Publication type:
- Article
New chemiluminescent enzyme immunoassay for quantitative measurement of Mac-2 binding protein glycosylation isomer in chronic liver disease.
- Published in:
- Journal of Gastroenterology, 2023, v. 58, n. 12, p. 1252, doi. 10.1007/s00535-023-02043-1
- By:
- Publication type:
- Article
Symptoms Contributing to the Diagnosis of Small Bowel Tumors.
- Published in:
- Digestion, 2023, v. 104, n. 6, p. 430, doi. 10.1159/000531215
- By:
- Publication type:
- Article
Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2014 to 2018 in Japan: A large‐scale multicenter retrospective study.
- Published in:
- Hepatology Research, 2023, v. 53, n. 11, p. 1059, doi. 10.1111/hepr.13947
- By:
- Publication type:
- Article
Agile 3+ and Agile 4, noninvasive tests for liver fibrosis, are excellent formulae to predict liver‐related events in nonalcoholic fatty liver disease.
- Published in:
- Hepatology Research, 2023, v. 53, n. 10, p. 978, doi. 10.1111/hepr.13938
- By:
- Publication type:
- Article
High intramuscular adipose tissue content was a favorable prognostic factor in patients with advanced gastric cancer treated with nivolumab monotherapy.
- Published in:
- Journal of Gastroenterology & Hepatology, 2023, v. 38, n. 10, p. 1760, doi. 10.1111/jgh.16239
- By:
- Publication type:
- Article
Efficacy of Lenvatinib Combined with Transcatheter Intra-Arterial Therapies for Patients with Advanced-Stage of Hepatocellular Carcinoma: A Propensity Score Matching.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 18, p. 13715, doi. 10.3390/ijms241813715
- By:
- Publication type:
- Article
The Incidence and Management of Cancer-Related Anorexia During Treatment with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors.
- Published in:
- Cancer Management & Research, 2023, v. 15, p. 1033, doi. 10.2147/CMAR.S417238
- By:
- Publication type:
- Article
Case Report: A case of complete response to entrectinib in NTRK fusion gene-positive parotid gland cancer.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1247435
- By:
- Publication type:
- Article
Impact of body fat accumulation on metabolic dysfunction‐associated fatty liver disease and nonalcoholic fatty liver disease in Japanese male young adults.
- Published in:
- Hepatology Research, 2023, v. 53, n. 8, p. 691, doi. 10.1111/hepr.13906
- By:
- Publication type:
- Article
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity.
- Published in:
- Clinical & Molecular Hepatology, 2023, v. 29, n. 3, p. 593, doi. 10.3350/cmh.2022.0391
- By:
- Publication type:
- Article
Telephone follow‐up contributes to improving adherence and treatment duration in patients with hepatocellular carcinoma treated with lenvatinib.
- Published in:
- Journal of Gastroenterology & Hepatology, 2023, v. 38, n. 7, p. 1140, doi. 10.1111/jgh.16168
- By:
- Publication type:
- Article
The impact of curative conversion therapy aimed at a cancer‐free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 11, p. 12325, doi. 10.1002/cam4.5931
- By:
- Publication type:
- Article
Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
- Published in:
- Journal of Gastroenterology, 2023, v. 58, n. 6, p. 565, doi. 10.1007/s00535-023-01985-w
- By:
- Publication type:
- Article
Twin Vibrational Power Generators and Extremum Seeking Control.
- Published in:
- IEEJ Transactions on Electrical & Electronic Engineering, 2023, v. 18, n. 6, p. 953, doi. 10.1002/tee.23789
- By:
- Publication type:
- Article
Multicenter, retrospective, cohort study shows platelet counts predict hepatocellular carcinoma development in patients with nonalcoholic fatty liver disease.
- Published in:
- Hepatology Research, 2023, v. 53, n. 5, p. 391, doi. 10.1111/hepr.13884
- By:
- Publication type:
- Article
Association of Serum Albumin Levels and Long-Term Prognosis in Patients with Biopsy-Confirmed Nonalcoholic Fatty Liver Disease.
- Published in:
- Nutrients, 2023, v. 15, n. 9, p. 2014, doi. 10.3390/nu15092014
- By:
- Publication type:
- Article
Safety of Early Bevacizumab Administration after Central Venous Port Placement for Patients with Colorectal Cancer.
- Published in:
- Cancers, 2023, v. 15, n. 8, p. 2264, doi. 10.3390/cancers15082264
- By:
- Publication type:
- Article
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective.
- Published in:
- Clinical & Molecular Hepatology, 2023, v. 29, n. 2, p. 242, doi. 10.3350/cmh.2023.0102
- By:
- Publication type:
- Article
N<sup>6</sup>-Methyladenosine Modification of ANLN Enhances Hepatocellular Carcinoma Bone Metastasis.
- Published in:
- International Journal of Biological Sciences, 2023, v. 19, n. 4, p. 1009, doi. 10.7150/ijbs.73570
- By:
- Publication type:
- Article
A low‐intensity 10‐min resistance exercise program that ameliorated hepatic fibrosis indices and altered G‐CSF/IP‐10/PDGF‐BB in a patient with nonalcoholic fatty liver disease: A case report.
- Published in:
- JGH Open, 2023, v. 7, n. 3, p. 231, doi. 10.1002/jgh3.12876
- By:
- Publication type:
- Article
The Inter-Organ Crosstalk Reveals an Inevitable Link between MAFLD and Extrahepatic Diseases.
- Published in:
- Nutrients, 2023, v. 15, n. 5, p. 1123, doi. 10.3390/nu15051123
- By:
- Publication type:
- Article
Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real‐world data.
- Published in:
- Hepatology Research, 2023, v. 53, n. 2, p. 116, doi. 10.1111/hepr.13852
- By:
- Publication type:
- Article
A combination of hepatic encephalopathy and body mass index was associated with the point of no return for improving liver functional reserve after sofosbuvir/velpatasvir treatment in patients with hepatitis C virus‐related decompensated cirrhosis
- Published in:
- Hepatology Research, 2023, v. 53, n. 1, p. 26, doi. 10.1111/hepr.13837
- By:
- Publication type:
- Article
Age‐dependent effects of diabetes and obesity on liver‐related events in non‐alcoholic fatty liver disease: Subanalysis of CLIONE in Asia.
- Published in:
- Journal of Gastroenterology & Hepatology, 2022, v. 37, n. 12, p. 2313, doi. 10.1111/jgh.16019
- By:
- Publication type:
- Article
Hepatic expression of sodium–glucose cotransporter 2 (SGLT2) in patients with chronic liver disease.
- Published in:
- Medical Molecular Morphology, 2022, v. 55, n. 4, p. 304, doi. 10.1007/s00795-022-00334-9
- By:
- Publication type:
- Article
Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-21528-2
- By:
- Publication type:
- Article
Metabolic dysfunction‐associated fatty liver disease directly related to liver fibrosis independent of insulin resistance, hyperlipidemia, and alcohol intake in morbidly obese patients.
- Published in:
- Hepatology Research, 2022, v. 52, n. 10, p. 841, doi. 10.1111/hepr.13808
- By:
- Publication type:
- Article
Utility of Diagnostic Colonoscopy in Pediatric Intestinal Disease.
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 19, p. 5747, doi. 10.3390/jcm11195747
- By:
- Publication type:
- Article
Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study.
- Published in:
- Cancers, 2022, v. 14, n. 17, p. 4284, doi. 10.3390/cancers14174284
- By:
- Publication type:
- Article
Case report: Changes in serum bevacizumab concentration in a hemodialysis patient with unresectable colorectal cancer treated with FOLFIRI plus bevacizumab.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.947013
- By:
- Publication type:
- Article
MAFLD associated with COPD via systemic inflammation independent of aging and smoking in men.
- Published in:
- Diabetology & Metabolic Syndrome, 2022, v. 14, n. 1, p. 1, doi. 10.1186/s13098-022-00887-w
- By:
- Publication type:
- Article
Editorial: The Metabolic (Dysfunction) Associated Fatty Liver Disease (MAFLD)-Non- Alcoholic Fatty Liver Disease (NAFLD) Debate: A Forced Consensus and The Risk of a World Divide.
- Published in:
- Medical Science Monitor, 2022, v. 28, p. 1, doi. 10.12659/MSM.938080
- By:
- Publication type:
- Article
Lean/normal‐weight metabolic dysfunction‐associated fatty liver disease is a risk factor for reflux esophagitis.
- Published in:
- Hepatology Research, 2022, v. 52, n. 8, p. 699, doi. 10.1111/hepr.13795
- By:
- Publication type:
- Article
Case Report: Exacerbation of varices following atezolizumab plus bevacizumab treatment of hepatocellular carcinoma: A case series and literature review.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.948293
- By:
- Publication type:
- Article
MAFLD: Renovation of clinical practice and disease awareness of fatty liver.
- Published in:
- Hepatology Research, 2022, v. 52, n. 5, p. 422, doi. 10.1111/hepr.13706
- By:
- Publication type:
- Article